Overview of RedirecTT-1, MagnetisMM-30 and MagnetisMM-5

Opinion
Video

Noopur Raje, MD, reviews clinical research on elranatamab combination therapy in patients with relapsed/refractory multiple myeloma.

Video content above is prompted by the following:

Please comment on the clinical trials evaluating combination strategies with bispecifics:

  • Talquetamab
  • RedirecTT-1
  • Elranatamab
  • MagnetisMM-30
  • MagnetisMM-5 
Recent Videos
A panel of 5 experts on multiple myeloma
A panel of 5 experts on multiple myeloma
A panel of 4 experts on multiple myeloma
4 KOLs are featured in this series
Samantha Shenoy, NP, MSN, discussed common oral and dermatologic adverse effects associated with talquetamab in patients with myeloma.
Combination therapy with JAK inhibitors may help improve efficacy outcomes for patients with multiple myeloma.
James R. Berenson, MD, discussed adverse effects associated with oral ruxolitinib plus selinexor in patients with multiple myeloma.
4 KOLs are featured in this series
4 KOLs are featured in this series
A panel of 5 experts on multiple myeloma
Related Content
The combination of talquetamab plus daratumumab yields improved patient outcomes in those with relapsed/refractory multiple myeloma.

Talquetamab/Daratumumab Shows Durable Responses in R/R Multiple Myeloma

Harrison Widelitz
September 27th 2024
Article

The combination of talquetamab plus daratumumab yields improved patient outcomes in those with relapsed/refractory multiple myeloma.

Registered nurses discuss research related to agents like ciltacabtagene autoleucel presented at the 2024 Oncology Nursing Society Congress.

Administering CAR T-Cell Therapy and Bispecific Agents in Nursing Practice

Ishmael Applewhite, BSN, RN-BC, OCN;Leslie Bennett, MSN, RN;Kathy Mooney, MSN, RN, ACNS-BC, BMTCN®, OCN®
May 6th 2024
Podcast

Registered nurses discuss research related to agents like ciltacabtagene autoleucel presented at the 2024 Oncology Nursing Society Congress.

Multiple myeloma

Daratumumab Regimens Improve Depth, Durability of MRD-Negativity Rates in Newly Diagnosed Multiple Myeloma

Harrison Widelitz
September 26th 2024
Article

Extended follow-up from the CASSIOPEIA trial illustrates the PFS and MRD benefits of daratumumab-based induction/consolidation and maintenance therapy.

Experts discuss key data updates in real-world newly diagnosed multiple myeloma practices, and how these findings may change the treatment paradigm.

Frontline Forum: Real-World Practice in Newly Diagnosed Multiple Myeloma

Joselle Cook, MBBS, Mayo Clinic;Matthew James Pianko, MD;Luciano Costa, MD, PhD;Timothy Schmidt, MD
August 14th 2023
Podcast

Experts discuss key data updates in real-world newly diagnosed multiple myeloma practices, and how these findings may change the treatment paradigm.

Responses appear to improve over time in those with transplant-eligible newly diagnosed multiple who receive the belantamab mafodotin-based combination.

Belantamab Combo Shows Promising Outcomes in Transplant-Eligible NDMM

Russ Conroy
September 26th 2024
Article

Responses appear to improve over time in those with transplant-eligible newly diagnosed multiple who receive the belantamab mafodotin-based combination.

Long-Term Data Affirm Enduring Responses With Teclistamab in R/R Multiple Myeloma

Long-Term Data Affirm Enduring Responses With Teclistamab in R/R Multiple Myeloma

ONCOLOGY Staff
September 22nd 2024
Article

Amrita Y. Krishnan, MD, and Binod Dhakal, MD, gave a high-level overview of teclistamab use in the MajesTEC-1 trial.